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Background:  Subjects unresponsive to erythropoietic stimulating agents (ESAs) suffer increased adverse outcomes when dosed to achieve 
hemoglobin targets without regard for ESA sensitivity. Often, ESAs are used in volume overload states, i.e. renal dysfunction and heart failure which 
are associated with hemodilutional anemia. Accordingly, we sought to evaluate differences in blood volume between ESA responders and non-
responders to ESAs.
Methods:  In an ongoing, randomized, single blind trial (NCT 00286182) of epoeitin alfa in older adults with anemia and heart failure and a 
preserved ejection fraction (HFPEF), blood volumes were measured using a radio-labeled albumin technique. We compared these measures in 
subjects who responded to ESA (greater than 1 gm/dl increase after 4 weeks of ESA therapy) to non-responders and those in placebo.
Results: In this trial (n=50) of older (78±11, range 55-100 years), mostly female (64%), obese (BMI 32±6), diabetic (64%) subjects with HFPEF 
and anemia, half randomized to active therapy were non-responders. Shown below, elevated BMI, diabetes and serum albumin differed between 
responders, non-responders and placebo subjects. However, measures of blood volume did not differ between cohorts.
Conclusions:  Unresponsiveness to ESAs is common among subjects with HFPEF and is not explained by the presence of a hemodilutional (e.g. 
false) anemia. Identifying the unresponsive subgroup using other criteria will be critical to evaluate use of ESAs in this population. 
Variable
Group
P ValuePlacebo
(n=26)
Non-responders
(n=11)
Responders
(n=11)
Demographics
Age - yr 80±11.9 76.5±5.3 74.4±11.5 NS
Gender - (%F) 62 73 64 NS
BMI 30.7±5.3 35.2±6 29.8±5 0.05
Diabetes Mellitus 12 (46.2) 11 (100) 8 (72.7) 0.0032
Lab tests
Transferrin saturation 19.9±14.3 18.9±9.2 20.2±18.6 NS
Erythropoietin 21.7±20.9 21.1±23.9 24.5±10.8 NS
Total proteins 6.8±0.7 6.7±0.4 7±0.4 NS
Albumin 3.7±0.6 3.6±0.3 4.1±0.3 0.03
B type natriuretic peptide 371.8±349.1 432.8±308.5 435.1±374.1 NS
BUN 37.1±15.9 37.4±22.6 27.8±12 NS
Creatinine 1.5±0.8 1.6±0.8 1.5±0.5 NS
Glomerular filtration rate 48.2±18 48.2±23.1 47.5±13.9 NS
Blood Volume Analysis
BV deviation - % 7±15 4.3±16.3 5.3±10.2 NS
RCV deviation - % -18.8±9.4 -23.1±9.6 -22.5±13 NS
PV deviation - % 23.5±22.4 21.4±25.2 22.5±12.1 NS
